NEW YORK – Immunogenomics startup Immunis.AI, once called OncoCell MDx, is eyeing the commercial launch of its prostate cancer surveillance laboratory-developed test, which leverages its immune-based liquip biopsy platform, by early 2021, the company said.
The Royal Oak, Michigan-based firm also aims to finalize an independent validation study for the prostate cancer signature assay within the next two months.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.